Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Doptelet (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure and for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
• This summary is based on the review of 13 systematic review(s)/meta-analysis(es). ^[1-13]
• Avatrombopag demonstrated a significantly higher platelet response compared to placebo (OR: 17.71, 95% CI: 11.01-28.48) and was more effective than eltrombopag and rhTPO in network meta-analyses (OR: 7.42; 95% CI: 1.74-31.69).
• Avatrombopag showed an increase in durable platelet response rates relative to placebo, and a reduction in the need for rescue therapy and the use of concomitant ITP medication.
• In patients with chronic liver disease, avatrombopag significantly increased preoperative platelet counts and reduced platelet transfusions compared to placebo.
• Compared to eltrombopag and romiplostim, avatrombopag had a lower incidence of any bleeding events (IRR 0.38 for both comparisons).
• Avatrombopag did not exhibit a significantly higher incidence of serious adverse events compared to placebo (RR: 1.18, 95% CI: 0.72-1.93), but general adverse events were slightly higher in avatrombopag-treated patients (RR: 1.25, 95% CI: 1.05-1.49).
• No significant increase in thrombotic events was observed with avatrombopag compared to placebo (OR=4.15, 95% CI: 0.20-85.23), and a meta-analysis suggested non-peptide TPO-RAs, including avatrombopag, were relatively safe concerning thrombotic events within 6 months (RR=1.92, 95% CI: 0.55-6.66).
• Subgroup analysis indicated that ITP patients with advanced age or a history of thrombosis had an increased thrombotic risk when receiving TAs therapy.
• There is no population type or subgroup information available in the reviewed studies.